Digital Callyope's AI-powered solution for mental health practitione... The state of the public’s mental health in the UK and Europe is a serious unmet need.
Patients Stronger together: The future of psychiatry in a changing Eu... Mental disorders account for a significant share of economic cost across EU Member States and the United Kingdom.
R&D 3 big unanswered questions about psychedelics When it comes to psychedelics in the mental health space, there are still some important foundational questions lacking settled answers.
Patients World Bipolar Day: Recognising bipolar I disorder and addres... BD-I is a brain-based condition that affects mood and energy regulation to an extent that disrupts daily life.
R&D Ending trial-and-error: How psychedelics and precision medic... The next phase of psychiatry must go toward treatments that are not only novel, but practical, personalised, and accessible.
News Precision psychiatry push starts in Europe As geopolitical tensions ratchet up around the world, an initiative has been launched to drive improvements in diagnostic accuracy and precision care.
News UK's Mission divests kidney drug to Dimerix for $292m Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
